WALTHAM, Mass.--(BUSINESS WIRE)--Repligen Corporation (NASDAQ:RGEN) today announced the launch of its new larger-scale OPUS™ brand chromatography columns used in the manufacture of biopharmaceuticals. The OPUS™ (Open Platform User Specified) line extension is being introduced in response to rising market demand for disposable technologies in biopharmaceutical manufacturing. Such technologies are revolutionizing biomanufacturing by enabling increased facility flexibility and operating efficiencies. The new OPUS™ chromatography columns are now commercially available to biopharmaceutical manufacturers and developers worldwide.
